20 results
PRE 14A
QNCX
Quince Therapeutics Inc
4 Apr 23
Preliminary proxy
4:33pm
effectiveness. Further, our board of directors is committed to actively seeking highly qualified women and individuals from minority groups to include
424B5
z2c5awygt7cco846
19 May 22
Prospectus supplement for primary offering
4:44pm
POS AM
omr jcl6xax3
4 Mar 22
Prospectus update (post-effective amendment)
4:04pm
POSASR
5z4kox
7 Feb 22
Automatic shelf registration (post-effective amendment)
5:01pm
424B5
oegs0ua
23 Dec 21
Prospectus supplement for primary offering
5:24pm
S-3ASR
bl2g ebo6ccfx2wpcwbp
1 Jun 20
Automatic shelf registration
4:46pm
DEF 14A
ti2dl2ehw
22 Apr 20
Definitive proxy
3:26pm
10-K
EX-4.3
ggy6h8x
16 Mar 20
Annual report
4:16pm
424B4
0dy4km51 iq36
9 May 19
Prospectus supplement with pricing info
5:14pm
S-1/A
uyqtrvn1wi8
16 Apr 19
IPO registration (amended)
6:04am
S-1
7fn78holt7lo
12 Apr 19
IPO registration
5:20pm
DRS
a6o 8u5f95q52o
4 Mar 19
Draft registration statement
12:00am
- Prev
- 1
- Next